Resources
7 Results (showing 1 - 7)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 10/23/2023 (updated 3/27/2024)
The Reagan-Udall Foundation partnered with the Food and Drug Administration (FDA) for the "Mitigating Risks from Human Xylazine Exposure" virtual and in-person webinar that occurred early October 2023. This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research that directly supports the mitigation and reduction of risks associated with human exposure to xylazine. The meeting materials, recordings, and slides are now available for viewing.
Posted 9/25/2023 (updated 3/27/2024)
The Bureau of Justice Assistance’s (BJA) Comprehensive Opioid, Stimulant, and Substance Use Program (COSSUP) has provided events and resources throughout September 2023 for National Recovery Month.
Posted 6/2/2023 (updated 3/27/2024)
Behavioral health care encompasses a wide variety of interventions delivered by many different types of providers. Although there is a call for expanding direct or indirect behavioral health service systems to care for those affected, in the U.S., nearly all these providers are in short supply.
Posted 3/10/2021 (updated 4/5/2024)
The 2020 National Drug Threat Assessment (NDTA) is a comprehensive assessment of the threat posed to the United States by the trafficking and abuse of illicit drugs, the diversion and abuse of licit drugs, and the laundering of proceeds generated through illicit drug sales. It also addresses the role domestic groups, including organized violent gangs, serve in domestic drug trafficking. The most widely trafficked drugs are discussed in terms of their availability, consumption and overdose related deaths, production and cultivation, transportation, and distribution.
Posted 9/25/2020 (updated 3/29/2024)
In its annual report, the Substance Abuse and Mental Health Services Administration (SAMHSA) presents data on the use of illicit drugs, alcohol, and tobacco, as well as trends in mental health and access to treatment.
Posted 9/1/2020 (updated 3/29/2024)
To raise awareness of increasing overdose events and deaths related to cocaine and other stimulant use, and to provide guidance to health care providers on clinically managing and preventing harm from cocaine and stimulant use disorders.
Posted 8/11/2020 (updated 4/2/2024)
Non-fatal opioid overdose (NFOO) is a significant cause of opioid-related morbidity in the United States. As the number of NFOOs continues to grow, it is important to understand the short- and long-term consequences of NFOO. This report examines the existing literature on the acute and chronic health and functional outcomes of individuals who experience NFOO, and also identifies differences in outcomes for NFOOs involving illicitly-manufactured fentanyl.